The Hidden Barrier to Better Healthcare
The following is a guest article by Josh Miller, Co-Founder & CEO at Gradient Health.
As a global society, we have never spent more on healthcare. We have never been more informed. We’ve never been…
Tag: North Carolina
UNC Health to Open New Youth-Specific Psychiatric Hospital to Address the Mental Health Crisis
North Carolina is among the bottom 10 states in the country when it comes to investment in child and adolescent mental health services — 42 out of 50 to be exact, said Dr. Samantha…
Continue Reading
Care Delivery Is Transforming. So Too Must The Role Of The Physician
I practiced cardiology in North Carolina for nearly 15 years. Many of my patients lived in rural, underserved communities. The effectiveness of my clinical practice was largely informed by my ability to reach my…
Continue Reading
Addressing the Diversity Challenge in Clinical Research Through Patient Advocacy
Andrew Barnhill, Head of Public Policy, Global Legal, IQVIAAlexandra Weiss, Director of Strategic Partnerships, Patient Advocacy Organizations, IQVIADiversity is paramount to the success of clinical research, both ethically and scientifically. Without adequate representation of…
Continue Reading
Moderna Signs On a New Partner in Quest for In Vivo mRNA Gene Editing
Moderna’s ambitions in messenger RNA technology include therapies that do their editing work inside the patient. To that end, the biotech company is starting an R&D collaboration with a division of ElevateBio that brings…
Continue Reading
How Blue Cross NC Is Using Its Hybrid Work Model to Battle Food Insecurity
Due to Covid-19, many companies moved to a hybrid work model, leading to their buildings being largely underutilized. Blue Cross and Blue Shield of North Carolina (Blue Cross NC), is taking advantage of its quieter workspace to fight food insecurity in its local communities.
Due to fewer employees working onsite, Blue Cross…
Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer
G1 Therapeutics’ approach to cancer does not kill tumors. Instead, the biotech’s drug, trilaciclib, protects bone marrow from the damaging effects of chemotherapy, reducing the duration and severity of the problems that can limit the use of this cancer treatment. Since trilaciclib’s initial approval insmall cell lung cancer, G1 has pursued more clinical trials that could support expanding the drug to other cancers. Colorectal cancer will no longer be one of them.
On Monday, G1 reported preliminary data showing that the placebo group outperformed the trilaciclib arm in helping patients live longer. G1 said it has decided to stop the colorectal cancer…
Farzad Mostashari, Aledade, on the power of primary care
Subscribe for your weekly fix of health tech stories, wherever you get your news: Substack, Twitter, Apple, or Spotify.Farzad Mostashari, co-founder & CEO of AledadeOur guest on this episode is Dr. Farzad Mostashari. Farzad is the…
Continue Reading